Significant differences between crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: Results from a european multicenter study in 1,176 patients

Digestive Diseases and Sciences

Volumn 55, Issue 4, 2010, Pages 1066-1078

  Holtmann, Martin H ^a   Krummenauer, Frank ^a   Claas, Christina ^a   Kremeyer, Kristina ^a   Lorenz, Dirk ^a   Rainer, Olivia ^a   Vogel, Iris ^a   Böcker, Ulrich ^b   Böhm, Stephan ^c   Büning, Carsten ^d   Duchmann, Rainer ^d   Gerken, Guido ^e   Herfarth, Hans ^f   Lügering, Norbert ^g   Kruis, Wolfgang ^h   Reinshagen, Max ⁱ   Schmidt, Jan ^j   Stallmach, Andreas ^k   Stein, Jürgen ^l   Sturm, Andreas ^m   Galle, Peter R ^a   Hommes, Daan W ⁿ   D'Haens, Geert ^o   Rutgeerts, Paul ^o   Neurath, Markus F ^a   more..

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h Department of Internal Medicine   (Germany)

ⁱ UNIVERSITY HOSPITAL ULM   (Germany)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^k JENA UNIVERSITY HOSPITAL   (Germany)

^l GOETHE UNIVERSITY   (Germany)

^m HUMBOLDT UNIVERSITY   (Germany)

ⁿ ACADEMIC MEDICAL CENTER   (Netherlands)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Azathioprine; Body mass index; Crohn's disease; Disease activity; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; PREDNISOLONE; STEROID; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BODY MASS; CROHN DISEASE; DISEASE ACTIVITY; DRUG DOSE COMPARISON; ENTERITIS; EUROPE; HEALTH SURVEY; HUMAN; IMMUNOREGULATION; INCIDENCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; ULCERATIVE COLITIS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; MULTICENTER STUDY; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; BODY MASS INDEX; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREDNISOLONE; RECURRENCE; TREATMENT OUTCOME;

EID: 77950345922     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0846-9     Document Type: Article

References (39)

1. W Sandborn L Sutherland D Pearson G May R Modigliani C Prantera 2000 Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease Cochrane Database Syst Rev 2 CD000545 10796557
2. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Chochrane Database Syst Rev. 2000;(2):CD000067.
3. Y Bouhnik M Lemann JY Mary G Scemama R Tai C Matuchansky R Modigliani JC Rambaud 1996 Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine Lancet 8996 215 219 10.1016/S0140-6736(96) 90402-X 10.1016/S0140-6736(96)90402-X (Pubitemid 26035245)
4. MH Holtmann F Krummenauer C Claas K Kremeyer D Lorenz O Rainer I Vogel U Bocker S Bohm C Buning R Duchmann G Gerken H Herfarth N Lugering W Kruis M Reinshagen J Schmidt A Stallmach J Stein A Sturm PR Galle DW Hommes G D'Haens P Rutgeerts MF Neurath 2006 Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1,176 patients Dig Dis Sci 9 1516 1524 10.1007/s10620-005-9037-5 10.1007/s10620-005-9037-5 (Pubitemid 44379292)
5. M Lemann JY Mary JF Colombel B Duclos JC Soule E Lerebours R Modigliani Y Bouhnik 2005 A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine Gastroenterology 7 1812 1818 10.1053/j.gastro.2005.03.031 10.1053/j.gastro.2005.03.031 (Pubitemid 40824692)
6. JL Rosenberg AJ Wall B Levin HJ Binder JB Kirsner 1975 A controlled trial of azathioprine in the management of chronic ulcerative colitis Gastroenterology 1 96 99
7. K Ewe AG Press CC Singe M Stufler B Ueberschaer G Hommel KH Meyer zum Buschenfelde 1993 Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease Gastroenterology 2 367 372
8. WJ Sandborn WJ Tremaine DC Wolf SR Targan CA Sninsky LR Sutherland SB Hanauer JW McDonald BG Feagan RN Fedorak KL Isaacs MG Pike DC Mays JJ Lipsky S Gordon CS Kleoudis RH Murdock Jr 1999 Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group Gastroenterology 3 527 535 10.1016/S0016-5085(99)70445-2 10.1016/S0016-5085(99)70445-2 (Pubitemid 29409238)
9. DH Present P Rutgeerts S Targan SB Hanauer L Mayer RA van Hogezand DK Podolsky BE Sands T Braakman KL DeWoody TF Schaible SJ van Deventer 1999 Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 18 1398 1405 10.1056/NEJM199905063401804 10.1056/NEJM199905063401804 (Pubitemid 29205403)
10. SR Targan SB Hanauer SJ van Deventer L Mayer DH Present T Braakman KL DeWoody TF Schaible PJ Rutgeerts 1997 A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group N Engl J Med 15 1029 1035 10.1056/NEJM199710093371502 10.1056/NEJM199710093371502 (Pubitemid 27430520)
11. GR Lichtenstein S Yan M Bala M Blank BE Sands 2005 Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease Gastroenterology 4 862 869 10.1053/j.gastro.2005.01.048 10.1053/j.gastro.2005.01.048 (Pubitemid 40523539)
12. P Rutgeerts WJ Sandborn BG Feagan W Reinisch A Olson J Johanns S Travers D Rachmilewitz SB Hanauer GR Lichtenstein WJ de Villiers D Present BE Sands JF Colombel 2005 Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 23 2462 2476 10.1056/NEJMoa050516 10.1056/NEJMoa050516 (Pubitemid 41770166)
13. G D'Haens F Baert G van Assche P Caenepeel P Vergauwe H Tuynman M De Vos S van Deventer L Stitt A Donner S Vermeire FJ Van de Mierop JC Coche J van der Woude T Ochsenkuhn AA van Bodegraven PP Van Hootegem GL Lambrecht F Mana P Rutgeerts BG Feagan D Hommes 2008 Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Lancet 9613 660 667 10.1016/S0140-6736(08)60304-9 10.1016/S0140-6736(08)60304-9 (Pubitemid 351284485)
14. Lees CW, Satsangi J. Early combined immunosuppression in Crohn's disease. Lancet. 2008;9629:1995; author reply 1996-1997.
15. Badina L, Taddio A, Ventura A. Early combined immunosuppression in Crohn's disease. Lancet. 2008;9629:1995; author reply 1996-1997.
16. R Lago R Gomez F Lago J Gomez-Reino O Gualillo 2008 Leptin beyond body weight regulation-current concepts concerning its role in immune function and inflammation Cell Immunol 1-2 139 145 10.1016/j.cellimm.2007.09.004 10.1016/j.cellimm.2007.09.004
17. A Schaffler J Scholmerich B Salzberger 2007 Adipose tissue as an immunological organ: toll-like receptors, C1q/TNFs and CTRPs Trends Immunol. 9 393 399 10.1016/j.it.2007.07.003 10.1016/j.it.2007.07.003 (Pubitemid 47385374)
18. K Karmiris IE Koutroubakis C Xidakis M Polychronaki T Voudouri EA Kouroumalis 2006 Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease Inflamm Bowel Dis. 2 100 105 10.1097/01.MIB.0000200345.38837.46 10.1097/01.MIB.0000200345.38837.46
19. AR Moschen A Kaser B Enrich B Mosheimer M Theurl H Niederegger H Tilg 2007 Visfatin, an adipocytokine with proinflammatory and immunomodulating properties J Immunol 3 1748 1758
20. B Siegmund JA Sennello J Jones-Carson F Gamboni-Robertson HA Lehr A Batra I Fedke M Zeitz G Fantuzzi 2004 Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice Gut. 7 965 972 10.1136/gut.2003.027136 10.1136/gut.2003.027136 (Pubitemid 38824154)
21. T Stroh A Batra R Glauben I Fedke U Erben A Kroesen MM Heimesaat S Bereswill S Girardin M Zeitz B Siegmund 2008 Nucleotide oligomerization domains 1 and 2: regulation of expression and function in preadipocytes J Immunol 5 3620 3627
22. J Cosnes I Nion-Larmurier L Beaugerie P Afchain E Tiret JP Gendre 2005 Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery Gut. 54 237 241 10.1136/gut.2004.045294 10.1136/gut.2004.045294 1:STN:280:DC%2BD2M%2FitFSrsw%3D%3D 15647188 (Pubitemid 40139240)
23. A Alves Y Panis F Joly M Pocard A Lavergne-Slove Y Bouhnik P Valleur 2004 Could immunosuppressive drugs reduce recurrence rate after second resection for Crohn's disease? Inflamm Bowel Dis. 10 491 495 10.1097/00054725-200409000-00001 10.1097/00054725-200409000-00001 15472507 (Pubitemid 39276454)
24. E Cuillerier M Lemann Y Bouhnik M Allez JC Rambaud R Modigliani 2001 Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study Eur J Gastroenterol Hepatol 13 1291 1296 10.1097/00042737-200111000-00005 10.1097/00042737-200111000-00005 1:CAS:528:DC%2BD38XlvFKgtw%3D%3D 11692053 (Pubitemid 33111973)
25. Myrelid P, Svarm S, Andersson P, Almer S, Bodemar G, Olaison G. Azathioprine as a postoperative prophylaxis reduces symptoms in aggressive Crohn's disease. Scand J Gastroenterol. 2006;1190-1195.
26. AG Fraser TR Orchard DP Jewell 2002 The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review Gut 50 485 489 10.1136/gut.50.4.485 1:CAS:528:DC%2BD38XislOqsLs%3D 11889067 (Pubitemid 34638866)
27. S Candy J Wright M Gerber G Adams M Gerig R Goodman 1995 A controlled double blind study of azathioprine in the management of Crohn's disease Gut 5 674 678 10.1136/gut.37.5.674
28. G Fantuzzi 2005 Adipose tissue, adipokines, and inflammation J Allergy Clin Immunol 5 911 999 10.1016/j.jaci.2005.02.023 quiz 920 (Pubitemid 40616201)
29. K Karmiris IE Koutroubakis EA Kouroumalis 2008 Leptin, adiponectin, resistin, and ghrelin-implications for inflammatory bowel disease Mol Nutr Food Res 8 855 866 10.1002/mnfr.200700050
30. A Fukuhara M Matsuda M Nishizawa K Segawa M Tanaka K Kishimoto Y Matsuki M Murakami T Ichisaka H Murakami E Watanabe T Takagi M Akiyoshi T Ohtsubo S Kihara S Yamashita M Makishima T Funahashi S Yamanaka R Hiramatsu Y Matsuzawa I Shimomura 2005 Visfatin: a protein secreted by visceral fat that mimics the effects of insulin Science 5708 426 430 10.1126/science.1097243 (Pubitemid 40139988)
31. Valenti L, Wirth EK, Schweizer U, Henstermann S, Schaper L, Koernicke T, Dietz E, Norman K, Buning C, Winklhofer-Roob BM, Lochs H, Ockenga J. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition. 2009;25(2):172-181.
32. AK Akobeng AG Thomas 2007 Enteral nutrition for maintenance of remission in Crohn's disease Cochrane Database Syst Rev 3 CD005984 17636816
33. Vighi G, Marcucci F, Sensi L, Di Cara G, Frati F. Allergy and the gastrointestinal system. Clin Exp Immunol. 2008;3-6.
34. EE Moore TN Jones 1986 Benefits of immediate jejunostomy feeding after major abdominal trauma-a prospective, randomized study J Trauma 10 874 881 10.1097/00005373-198610000-00003
35. KA Kudsk MA Croce TC Fabian G Minard EA Tolley HA Poret MR Kuhl RO Brown 1992 Enteral versus parenteral feeding. Effects on septic morbidity after blunt and penetrating abdominal trauma Ann Surg 5 503 511 discussion 511-513
36. RL Jump AD Levine 2004 Mechanisms of natural tolerance in the intestine: implications for inflammatory bowel disease Inflamm Bowel Dis 4 462 478 10.1097/00054725-200407000-00023 (Pubitemid 39029194)
37. W Kang FE Gomez J Lan Y Sano C Ueno KA Kudsk 2006 Parenteral nutrition impairs gut-associated lymphoid tissue and mucosal immunity by reducing lymphotoxin Beta receptor expression Ann Surg 3 392 399
38. I Tiede G Fritz S Strand D Poppe R Dvorsky D Strand HA Lehr S Wirtz C Becker R Atreya J Mudter K Hildner B Bartsch M Holtmann R Blumberg H Walczak H Iven P Galle MR Ahmadian 2003 MF Neurath. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes J Clin Invest 111 1133 1145 1:CAS:528:DC%2BD3sXjtFCrsrY%3D 12697733
39. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;1861-1874.